Returning to work after sick leave due to cancer: a 365-day cohort study of Japanese cancer survivors

Motoki Endo¹ · Yasuo Haruyama² · Miyako Takahashi³ · Chihiro Nishiura⁴ · Noriko Kojimahara¹ · Naohito Yamaguchi¹

Abstract

Purpose More employees are experiencing a cancer diagnosis during their working-age years, yet there have been no large-scale Japanese studies investigating sick leave due to cancer. We clarified differences in the cumulative partial and full return to work (RTW) rates between different cancer types among Japanese cancer survivors.

Methods Data on Japanese employees who experienced an episode of sick leave due to clinically certified cancer diagnosed between 1 January 2000 and 31 December 2011 were obtained from an occupational health register. Subject outcomes within the 365-day period following their initial day of sick leave were utilized for this study. We investigated the cumulative partial/full and full RTW rates by using survival analysis with competing risks and predictors of time to RTW by a Fine-Gray proportional hazard regression model.

Results One thousand two hundred seventy-eight subjects (1033 males and 245 females) experienced their first episode of sick leave due to cancer during the 12-year follow-up period. Of the subjects, 47.1% returned to work full time within 6 months of their initial day of sick leave absence, and 62.3% by 12 months. The cumulative RTW rate varied significantly by cancer type. There were considerable differences in the range of cumulative full RTW rates between the two categories (“lower full RTW rate” groups (“lung,” “hepatic, pancreatic,” “esophageal,” and “blood” cancer groups) vs. “higher full RTW rate” groups (“gastric,” “intestinal,” “breast,” “female genital,” “male genital,” “urinary”): 6.3 to 14.3% vs. 11.4 to 28.3% at 60 days, 10.6 to 22.4% vs. 27.0 to 50.0% at 120 days, 21.3 to 34.7% vs. 38.5 to 65.4% at 180 days, 34.3 to 42.9% vs. 66.0 to 79.5% at 365 days). Additionally, older age may be associated with a longer time to full RTW.

Conclusions More than half of the subjects returned to work full-time within the 365-day period following their initial day of sick leave, with cumulative RTW rates varying by cancer type. Older employees may require a longer time to full RTW.

Implications of Cancer Survivors It is very important for companies (especially small- and medium-sized companies) to establish and improve their RTW support system for cancer survivors, with knowledge that the median time to RTW is expected to be at least a few months.

Keywords Cancer survivors · Sick leave · Cumulative return to work (RTW) rate · Partial RTW system · Longitudinal study

Introduction

Cancer is still one of the leading causes of morbidity and mortality worldwide [1–3]. Public health and medicine for cancer have improved remarkably in recent years [1, 2]. Advances in early diagnosis and effective multidisciplinary treatment have decreased the impact of cancer on the life of cancer survivors [4], and the 5-year survival rate for many kinds of cancers has steadily increased in most developed countries [5–7]. With the aging population, and prolonged cancer survival, the prevalence of cancer survivors is expected to further increase in the near future in most countries [8, 9].
Correspondingly, previous Japanese studies have stated that many cancer patients are surviving longer than in previous decades [10, 11]. The incidence of cancer is higher in senior citizens [1]. However, in fact, according to Japanese cancer surveillance, about 30% of all diagnosed cancer patients (805,236 patients) belonged to the 20- to 64-year-old working-age group (244,976 patients) in 2010 [12]. As the age of retirement will likely be increased in the future, it is estimated that more working-age employees are expected to experience a cancer diagnosis, as in Western countries [1, 13, 14]. With an increased incidence of cancer diagnoses in the working population, return to work (RTW) of cancer survivors is predicted to be an increasingly relevant situation for the individual, employers, and society [15].

In occupational health studies, RTW rates among cancer survivors vary remarkably in the literature despite comparable study populations [13, 16–18]. From a systematic review of 64 studies, 63.5% of cancer survivors returned to work after diagnosis [1]. RTW of cancer patients may be viewed as proof of complete recovery, which means that the individuals’ work capacity has recovered to a level that enables a return to work. The situation is generally more complex, affecting occupational rehabilitation and the process of RTW [16, 19]. If employers allow adjustments in work requirements, utilizing occupational health services, partial RTW, etc., RTW may improve the quality of life for cancer survivors by providing social reintegration and increasing self-esteem [20, 21].

To support effective occupational rehabilitation for cancer survivors, previous studies have focused more on the work adjustments provided after RTW [21]. However, less attention has been focused on the predictors of sickness absence duration due to cancer [9]. To the best of our knowledge, there has been no large-scale study in Japan investigating the work-related outcomes after the initial episode of sickness absence due to cancer, stratified by cancer site [22].

The objective of this study was to clarify differences in the cumulative partial/full and full RTW rates between different cancer sites among Japanese cancer survivors, in a 365-day period following the initial day of sickness absence due to cancer, and to investigate the importance of partial RTW at RTW among Japanese cancer survivors. By specifying the site-stratified cumulative RTW rates, this study may help companies establish and improve their RTW support system for cancer survivors.

Methods

This was a longitudinal study on the course of sickness absence among employees who were in the process of occupational rehabilitation after a diagnosis of cancer. Employees who experienced an episode of sickness absence due to clinically certified cancer diagnosed between 1 January 2000 and 31 December 2011 were included in this study. During this 12-year period, 1278 employees were diagnosed with cancer, and the 365-day period after their initial day of sickness absence due to cancer was investigated for each subject.

Registered data of sickness absence was obtained from a private occupational health center comprised of approximately 30 occupational physicians (OPs) and 75 occupational health nurses. The occupational health center contracted the OPs with approximately 35 large-scaled Japanese companies of various industries (telecommunications, logistics, energy, construction, etc.), to provide their employees with occupational health services. The total number of employees working for these companies on a full-time basis from 2000 to 2011 was approximately 68,000.

Sickness insurance system

In Japan, there is no law insuring sickness absence for employees who are not able to work. However, the Labor Contract Act states “A dismissal shall, if it lacks objectively reasonable grounds and is not considered to be appropriate in general societal terms, be treated as an abuse of right and be invalid” [3]. To our knowledge, almost all large Japanese companies have their own sickness insurance system for employees who cannot work due to cancer, depression, stroke, and so on. These sickness insurance systems are only for working individuals, and there is no limitation due to age as long as employees have been working. The time limit for sickness absence varies depending on the company. In the Japanese sickness absence system, part-time sickness absence combined with part-time work is not so common. The fact is that many small- and medium-sized enterprises in Japan do not have such an established sickness insurance system. We guess that cancer survivors who work at small- and medium-sized enterprises have no choice but to quit because of their companies’ economic circumstances, among other factors.

On the other hand, the large companies that we investigated in this study had the same well-established sickness insurance system, associated with their OP contract. The occupational health service registration system of sickness absence and RTW in our study was as follows: after diagnosis of cancer, to certify an episode of sickness absence, an employee was required to submit a physician’s certificate stating that the employee was unable to work due to cancer. In general, the treatment for cancer has a more negative effect on the individual’s work capacity than the cancer itself. The OP confirmed the medical validity of the issued physician’s certificate, and the certificate was sent to the human resources department, of which only the data of full-time workers was registered. The cause of sickness absence was recorded by the OPs, referring to the World Health Organization’s 10th International Classification of Diseases (ICD-10). Under the Labor Standards Law of Japan, employees absent due to sickness...
were allowed approximately two thirds of their regular salary. In the sickness insurance system, there is no limitation due to age. The time limit for sickness absence due to cancer is set by the OP contract as 3 years. For RTW, employees were required to submit a physician’s certificate stating that they were fit for return to work, as well as participate in interviews with their company’s respective OPs for further confirmation that RTW was medically acceptable. OPs further determined whether the employee in question could return to work full-time (full RTW) or part time (partial RTW, usually 4 to 6 hours a day), and issue the OP’s RTW certificate to the company.

As shown in Table 1, the outcome after sickness absence was analyzed by cancer sites, which included more than 50 subjects. Of these, “gastric” cancers were the most prevalent (ICD-10: C16, n=282), followed by “lung” cancers (C33-C34, n=162), and “intestinal” cancers (C17-C21, n=146), which included small intestine cancer (n=7), colon cancer (n=70), and rectal or anal cancer (n=69). The fourth most prevalent was “hepatic, pancreatic” cancers (C22-C25, n=98), which included hepatocellular carcinoma (n=38), cholangiocarcinoma (n=9), gall bladder cancer (n=4), and pancreatic cancer (n=47). The fifth most prevalent was “breast” cancer (C50, n=97), involving only female employees. The sixth most prevalent was “blood” malignancies (C81-C96, n=95), which included leukemia (n=32), malignant lymphoma (n=46), multiple myeloma

| Cancer site                  | Number | Men  | Women | Mean age at diagnosis |
|------------------------------|--------|------|-------|-----------------------|
| Gastric                      | 282    | 262  | 20    | 52.9                  |
| Esophageal                   | 67     | 64   | 3     | 54.7                  |
| Intestinal                   | 146    | 140  | 6     | 51.9                  |
| Small intestine cancer       | 7      | 7    | 0     | 52.4                  |
| Colon cancer                 | 70     | 64   | 6     | 52.0                  |
| Rectal, anal cancer          | 69     | 69   | 0     | 51.8                  |
| Lung                         | 162    | 143  | 19    | 54.1                  |
| Hepatic, pancreatic          | 98     | 91   | 7     | 54.4                  |
| Hepatocellular carcinoma     | 38     | 36   | 2     | 52.6                  |
| Cholangiocarcinoma           | 9      | 7    | 2     | 57.3                  |
| Gall bladder cancer          | 4      | 4    | 0     | 57.8                  |
| Pancreatic cancer            | 47     | 44   | 3     | 54.9                  |
| Breast                       | 97     | 0    | 97    | 48.1                  |
| Female genital               | 67     | 67   | 0     | 46.4                  |
| Cancer of uterus             | 47     | 0    | 47    | 47.6                  |
| Ovarian cancer               | 20     | 0    | 20    | 43.8                  |
| Male genital                 | 78     | 78   | 0     | 53.0                  |
| Prostatic cancer             | 63     | 63   | 0     | 55.7                  |
| Testicular, penis cancer     | 15     | 15   | 0     | 41.5                  |
| Urinary                      | 53     | 52   | 1     | 53.2                  |
| Renal cell carcinoma, ureter carcinoma | 30 | 29   | 1     | 52.8                  |
| Bladder cancer               | 23     | 23   | 0     | 53.6                  |
| Blood                        | 95     | 86   | 9     | 49.0                  |
| Leukemia                     | 32     | 29   | 3     | 47.5                  |
| Malignant lymphoma           | 46     | 41   | 5     | 49.2                  |
| Multiple myeloma             | 8      | 8    | 0     | 54.0                  |
| Other related cancers        | 9      | 8    | 1     | 49.0                  |
| Other                        | 133    | 117  | 16    | 50.7                  |
| Brain cancer                 | 20     | 18   | 2     | 50.0                  |
| Oral cancer                  | 20     | 19   | 1     | 50.7                  |
| Pharyngo-laryngeal cancer    | 27     | 27   | 0     | 54.4                  |
| Thyroid cancer               | 19     | 9    | 10    | 47.9                  |
| Other cancers                | 47     | 44   | 3     | 49.9                  |
| Total                        | 1278   | 1033 | 245   | 51.9                  |
(n=8), and other related cancers (n=9). The seventh most prevalent was “male genital” cancers (C60-63, n=78), which included prostatic cancer (n=63) and testicular or penis cancer (n=15). Tied for the eighth most prevalent were “esophageal” cancer (C15, n=67) and “female genital” cancers (C51-C58, n=67), which included cancer of the uterus (n=47) and ovarian cancer (n=20). The tenth most prevalent was “urinary” cancers (C64-C68, n=53), which included renal cell carcinoma and ureter cancer (n=30), and bladder cancer (n=23). “Other” cancer (n=133) included brain cancer (C71, n=20), oral cancer (C00-C09, n=20), pharyngo-laryngeal cancer (C10-C14, n=27), thyroid cancer (C73, N=19), and others (n=47).

Statistical analysis

Subject outcomes within the 365-day period following their initial day of sickness absence were obtained from the register and utilized for this study. A 365-day period was arbitrarily chosen for ease of use for other Japanese companies to establish a RTW support system for cancer survivors.

Survival analysis with competing risks was performed to illustrate the cumulative RTW rates by using EZR [23]. We used Fine-Gray proportional hazard regression for competing events in order to analyze whether age, gender, and cancer sites were statistically associated with partial/full RTW and full RTW.

We assigned subjects to 5 categories: “died,” “resigned,” “disabled,” “full RTW,” and “partial RTW.” “Disabled” was defined as subjects who remained absent due to illness by the end of the 365-day period. “Died” and “resigned” were set as factors of competing risks for RTW.

In the Fine-Gray proportional hazard regression, a hazard ratio of more than 1 meant a shorter time to an event. Subjects were stratified by age into four groups by quartiles, resulting in the following age groups: 48 years or younger (reference), 49–52 years, 53–56 years, and 57 years or older.

This study was approved by the Medical Ethics Committee of Tokyo Women’s Medical University (number 3244).

Results

In the present study, 1278 subjects experienced their first episode of sickness absence due to cancer certified by their physicians, which means that these individuals had not had an episode of sickness absence due to cancer earlier. Shown in Table 1, the characteristics of the subjects were as follows: 1033 (80.8 %) of 1278 subjects were males and 245 (19.2 %) were females. The mean age at the initial day of sickness absence was 51.9 years.

The numbers of those having the event, as well as those who were censored before having the event, are shown in Table 2. After the 365-day period following the initial day of sickness absence, 35 subjects had resigned from their work, 132 subjects had died, and 74 employees had been classified as “disabled,” namely, being unable to return to work within the 365-day period. Approximately 31 of 98 subjects in the “hepatic, pancreatic” cancer group had died within the 365-day period following their initial day of sickness absence. The cancer survivors in the “female genital” cancer group did not die within the 365-day period. Resignation occurred frequently among subjects in the “esophageal cancer” group, with nine subjects resigning from their work within the 365-day period following their initial day of absence. There were no resignations from subjects in the “gastric,” “female genital,” or “urinary” cancer groups. The prevalence of “disabled” subjects was highest in the “blood” malignancies group, in which 19 subjects had a period of sickness absence exceeding 365 days. The “gastric” and “esophageal” cancer groups had the lowest prevalence of “disabled” subjects after the 365-day period. The median time to full RTW among all cancer survivors was 201 days. There were missing values regarding the median time to full RTW among “esophageal,” “lung,” “hepatic, pancreatic,” and “blood” malignancy groups because the cumulative full RTW rates did not reach 50 %. Approximately 3.5 times more subjects returned to work partially compared to full-time. When stratified by cancer site, the partial to full RTW ratio ranged from 1.6 (others) to 8.4 (esophageal cancer). As shown in Table 2, the median duration of sickness absence until either partial or full RTW was 80 days. The median duration until full RTW was 201 days (about 6.5 months).

Figure 1 shows the duration of time until partial or full RTW for each cancer site. As the result of survival analysis with competing risks, the overall cumulative RTW rates after the initial day of sickness absence at 60, 120, 180, and 365 days were 41.0, 64.1, 71.6, and 80.9 % respectively.

Figure 2 shows the duration of time until full RTW. As the result of survival analysis accounting for competing risks, the cumulative full RTW rates at 60, 120, 180, and 365 days were 16.7, 34.9, 47.1, and 62.3 %, respectively. The ten different cancer site groups were approximately divided into two categories: those with a lower cumulative full RTW rate, consisting of the “lung,” “hepatic, pancreatic,” “esophageal,” and “blood” cancer groups, and those with a higher rate (“gastric,” “intestinal,” “breast,” “female genital,” “male genital,” “urinary”). There were considerable differences in the range of cumulative full RTW rates between the two categories (“lower full RTW rate” groups vs. “higher full RTW rate” groups: 6.3 to 14.3 % vs. 11.4 to 28.3 % at 60 days, 10.6 to
22.4% vs. 27.0 to 50.0% at 120 days, 21.3 to 34.7% vs. 38.5 to 65.4% at 180 days, 34.3 to 42.9% vs. 66.0 to 79.5% at 365 days). The group with the lowest cumulative RTW rate (both total RTW and full RTW rates) was the blood malignancy group, whose cumulative total RTW rates at 60, 120, 180, and 365 days were 12.6, 27.4, 35.9, and 65.8 %, and whose cumulative full RTW rates were 6.3, 10.6, 21.3, and 42.9 %, respectively.

As shown in Table 3, as for cancer sites, employees with “esophageal,” “lung,” “hepatic, pancreatic,” and “blood” cancers had a longer time to partial/full RTW than those with “gastric” cancer.

As shown in Table 4, Fine-Gray regression analysis revealed that female subjects were not statistically associated with a longer time to full RTW (hazard ratio of female for time to full RTW was 1.07, 95% confidence interval 0.78–1.46), compared to male subjects. According to the multivariate analysis including all variables, subjects in the >57 year age groups had longer times to full RTW than the <48 year (reference) age group (the hazard ratio for RTW was 0.78, 95% confidence interval 0.64–0.97). In addition, those with “esophageal,” “lung,” “hepatic, pancreatic,” and “blood” cancers had a longer time to full RTW than those with “gastric” cancer.

**Discussion**

The growing prevalence of employees diagnosed with cancer has increased the necessity for better RTW support systems for cancer survivors, particularly for occupational health. To the best of our knowledge, this was the first large-scale study

**Table 2** Occupational register outcomes within 365 days after initial day of sickness absence, stratified by cancer site

| Cancer site            | Number | Median time to partial/full RTW (days) | Median time to full RTW (days) | 1. Died, N | 2. Resigned, N | 3. Disabled, N | 4. RTW, N | Full RTW, N | Partial RTW, N | Partial RTW/full RTW (ratio) |
|------------------------|--------|---------------------------------------|--------------------------------|------------|----------------|----------------|-----------|-------------|----------------|---------------------------|
| Gastric                | 282    | 62                                    | 124                            | 16         | 0              | 3              | 263       | 40          | 223           | 5.6                       |
| Esophageal             | 67     | 123                                   | –                              | 7          | 9              | 2              | 47        | 5           | 42            | 8.4                       |
| Intestinal             | 146    | 66.5                                  | 136.5                          | 16         | 3              | 4              | 123       | 31          | 92            | 3.0                       |
| Lung                   | 162    | 96.5                                  | –                              | 22         | 7              | 11             | 122       | 31          | 91            | 2.9                       |
| Hepatic, pancreatic    | 98     | 194                                   | –                              | 31         | 6              | 7              | 54        | 13          | 41            | 3.2                       |
| Breast                 | 97     | 91                                    | 209                            | 1          | 2              | 6              | 87        | 15          | 72            | 4.8                       |
| Female genital         | 67     | 83                                    | 172                            | 0          | 0              | 5              | 62        | 11          | 51            | 4.6                       |
| Male genital           | 78     | 60.5                                  | 24.5                           | 1          | 4              | 5              | 68        | 16          | 52            | 3.3                       |
| Urinary                | 53     | 52                                    | 127                            | 7          | 0              | 1              | 45        | 15          | 30            | 2.0                       |
| Blood                  | 95     | 241                                   | –                              | 12         | 1              | 19             | 62        | 14          | 48            | 3.4                       |
| Other                  | 133    | 91                                    | 195                            | 19         | 3              | 11             | 98        | 38          | 60            | 1.6                       |
| Total                  | 1278   | 80                                    | 201                            | 132        | 35             | 74             | 1031      | 229         | 802           | 3.5                       |
in Japan identifying factors that influence cumulative RTW rates among cancer survivors, using survival analysis.

We found that 71.6 % of subjects returned to work (part-time or full-time) within 6 months of their initial day of sickness absence, and 80.9 % by 12 months. This is in accordance with findings from other Western studies stating that many cancer survivors return to work after sickness absence, and working ability improves over time [24–27]. For full RTW, 47.1 % of subjects returned to work full-time within 6 months of their initial day of sickness absence, and 62.3 % by 12 months in the present study, while a previous study reported rates of 60–89 % [27]. This discrepancy may be caused by differences in study population, design, and methodology [17, 28, 29].

Furthermore, as the result of our study considering competing risks, only 4.1 % of subjects resigned from their place of employment within 1 year of their initial day of sickness absence due to cancer, while approximately 8 % of cancer survivors resigned within 2 years in the Netherlands' study [17].

| Table 3 | Fine-Gray regression model for the time to partial/full RTW within 365 days |
|---------|--------------------------------------------------------------------------------|
| Variables | Categories | Univariable analyses | Multivariable analyses |
| | | HR (95 % CI) | P value | HR (95 % CI) | P value |
| Age (years) | | | | | |
| <48 (ref) | 1 | 1 | 1 |
| 49–52 | 0.96 (0.79–1.18) | 0.68 | 0.96 (0.78–1.18) | 0.68 |
| 53–56 | 0.99 (0.85–1.15) | 0.92 | 1.02 (0.87–1.20) | 0.77 |
| >57 | 0.86 (0.73–1.02) | 0.09 | 0.90 (0.75–1.07) | 0.24 |
| Sex | | | | | |
| Men (ref) | 1 | 1 | 1 |
| Women | 0.90 (0.78–1.03) | 0.11 | 0.85 (0.67–1.09) | 0.21 |
| Cancer sites | | | | | |
| Gastric (ref) | 1 | 1 | 1 |
| Esophageal | 0.54 (0.40–0.72) | <0.01 | 0.53 (0.40–0.72) | <0.01 |
| Intestinal | 0.94 (0.75–1.16) | 0.55 | 0.93 (0.75–1.16) | 0.53 |
| Lung | 0.68 (0.55–0.84) | <0.01 | 0.68 (0.55–0.84) | <0.01 |
| Hepatic, pancreatic | 0.40 (0.29–0.54) | <0.01 | 0.40 (0.30–0.55) | <0.01 |
| Breast | 0.82 (0.67–1.00) | 0.06 | 0.70 (0.52–0.95) | 0.02 |
| Female genital | 0.89 (0.70–1.13) | 0.34 | 0.76 (0.55–1.06) | 0.10 |
| Male genital | 1.03 (0.78–1.36) | 0.83 | 1.04 (0.79–1.38) | 0.77 |
| Urinary | 1.05 (0.73–1.52) | 0.78 | 1.06 (0.74–1.53) | 0.75 |
| Blood | 0.41 (0.32–0.52) | <0.01 | 0.40 (0.32–0.51) | <0.01 |
Cumulative RTW rate by cancer site

The cumulative RTW rate varied significantly by cancer site, in line with previous reports [17, 24, 28, 30]. The previous studies reported that lung cancer and blood malignancies had lower total RTW rate than other cancer sites [17, 31]. The differences observed in RTW rates between previous studies may be explained by differences in the company health care systems, and the particular country’s focus on preventive care [32].

Our study showed that the blood malignancy group had a lower cumulative RTW rate. Other studies have previously stated that blood malignancies were the most difficult cancers for cancer survivors to achieve RTW [19, 33]. In the aspect of clinical oncology, chemotherapy is indicated for all patients of blood malignancy, according to the Japanese Clinical Guidelines of Hematopoietic Tumor [34]. Chemotherapy for blood malignancies such as acute myeloid leukemia and Hodgkin’s disease is quite effective, whereas effectiveness may be significantly lower for other cancer types [35]. However, it has been reported that patients with blood malignancies may be more severely affected by the side effects of chemotherapy [35]. One study reported that chemotherapy, which normally continues for several months, decreases the quality of life of cancer patients, leading to symptoms such as general malaise, distress, mental disorders [36, 37]. Prevention of depression may be one of the most important factors impacting RTW. Depression has been reported to have negative and long-time effects on cancer survivors, decreasing the general quality of life, worsening compliance with chemotherapy, and lengthening the duration of hospitalization [38, 39].

While a decrease in cumulative RTW rate may be due to the inclusion of patients with worse prognoses, chemotherapy itself may be one noteworthy factor influencing the duration of sickness absence [17, 25, 26, 40].

Time from initial day of sickness absence to RTW

The present study showed that cancer site was strongly associated with time to RTW, consistent with previous studies [41, 42], with the cumulative RTW rates of the esophageal, lung, hepatic, pancreatic, and blood cancer groups lower than the other groups.

The median time to partial or full RTW for each cancer site group, other than the esophageal and blood cancer groups, was approximately 3 months. By using a patient survey conducted in 2008 by the Ministry of Health, Labor and Welfare, the mean duration of hospitalization was compared with the median time to partial or full RTW for patients of each cancer site group; gastric cancer 27 days (duration of hospitalization) vs 62 days (duration of sickness absence), esophageal cancer 24 vs 96.5 days, lung cancer 26 vs 96.5 days, and breast cancer 16 vs 91 days [43]. These differences may be due to outpatient treatment (chemotherapy, radiotherapy, etc.), psychiatric impairment, or other factors.

The rate of RTW declined over time after the initial day of sickness absence; the RTW rate was highest in the first quarter of the year, followed by the second quarter, a tendency in accordance with previous studies [9, 17, 28, 31]. This may be due to the shape of the distribution of sickness absence,

| Table 4 | Fine-Gray regression model for the time to full RTW within 365 days |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Variables       | Categories       | Univariable analyses | Multivariable analyses |
| Age (years)     |                 | HR (95 % CI) | P value | HR (95 % CI) | P value |
| <48 (ref)       | 1               | 0.84 (0.67–1.05) | 0.13 | 0.89 (0.70–1.12) | 0.31 |
| 49–52           |                 | 0.80 (0.67–0.95) | 0.01 | 0.87 (0.73–1.04) | 0.14 |
| 53–56           |                 | 0.71 (0.58–0.86) | <0.01 | 0.78 (0.64–0.97) | 0.02 |
| >57             |                 | 1               | 1      | 1               | 1        |
| Sex             |                 |                 |       |                 |         |
| Men (ref)       | 1               | 0.88 (0.75–1.03) | 0.12 | 1.07 (0.78–1.46) | 0.69 |
| Women           |                 | 1               | 1      |                 |         |
| Cancer sites    |                 |                 |       |                 |         |
| Gastric (ref)   | 1               | 0.99 (0.79–1.24) | 0.18 | 0.98 (0.78–1.23) | 0.86 |
| Intestinal      |                 | 0.33 (0.24–0.45) | <0.01 | 0.29 (0.21–0.39) | <0.01 |
| Lung            |                 | 0.38 (0.26–0.55) | <0.01 | 0.39 (0.27–0.56) | <0.01 |
| Hepatic, pancreatic | 0.86 (0.69–1.08) | 0.19 | 0.86 (0.60–1.24) | 0.43 |
| Breast          |                 | 0.99 (0.76–1.30) | 0.96 | 0.99 (0.67–1.46) | 0.95 |
| Female genital  |                 | 1.18 (0.90–1.55) | 0.24 | 1.18 (0.89–1.55) | 0.25 |
| Male genital    |                 | 0.90 (0.61–1.34) | 0.61 | 0.90 (0.61–1.33) | 0.61 |
| Urinary         |                 | 0.38 (0.28–0.52) | <0.01 | 0.37 (0.27–0.51) | <0.01 |
| Blood           |                 | 1               | 1      |                 |         |
which has been reported to be heavily right-skewed [29]. While Christensen et al. reported that RTW rates decrease with increasing duration of sickness absence, occupational rehabilitation at the early stages of sickness absence may remain important [44].

In the present study, the Fine-Gray regression model for the total population demonstrated subjects in the >57 year age groups had a longer duration of sickness absence until full RTW compared to the <48 year age group. Some previous studies have reported that older cancer survivors require a longer time to RTW, whereas other studies were unable to show significant correlation between age and time to RTW [19, 41]. Roelen et al. reported age was correlated with full RTW in genital cancer survivors, but not for other cancers [17].

The present study showed that there was no significant association between time to full RTW and gender, in contrast with previous studies stating that “female” was negatively associated with RTW [1, 15, 41]. In a French study on the RTW process within 2 years of cancer diagnosis, the authors hypothesized that the difference observed between men and women may have been due to an increased incentive for men to RTW because of economic responsibility for their families [9]. A Dutch study demonstrated that gender was only associated with time to full RTW in patients diagnosed with a blood malignancy, observing that women took a longer time to full RTW compared with men [17].

Partial RTW and full RTW

In addition to the previous discussion, there were other large differences between the present Japanese study and previous Western ones [24, 28, 45]. The present study observed that many subjects returned to work part-time; in contrast, many of the subjects in the previously published studies returned to work full-time [24, 31, 39, 41]. Comparison of the present results with previous studies may be difficult using the values including both partial and full RTW.

The difference in cumulative RTW rates between Figs. 1 and 2 demonstrate that a “partial RTW system” for cancer survivors seemed to markedly improve cumulative RTW rates, except for the “blood” malignancies group. Thus, establishment of a partial RTW system in companies (especially small- and medium-sized companies) may improve cumulative RTW rates.

The ratio of partial RTW to full RTW among cancer site groups was highest in the “esophageal” cancer group, which may have possibly been due to a restriction in diet following esophageal surgery, leading to less physical strength and prevention of full-time work. However, decision of partial or full RTW was not based on an objective standard; rather, it was entirely based on the OPs’ subjective judgment. In general, RTW for cancer survivors is quite complex, depending on a variety of medical and non-medical factors [41]. Previous reports have stated that factors influencing RTW include socio-demographic factors (age, gender), disease-specific variables (site, stage, treatment, comorbidity), and social-environmental elements [45, 46]. As for disease-specific variables, various levels of symptom severity are associated with varying patterns of work disability [16]. In the present study, OPs were assumed to understand the disease-specific information of each subject for their RTW, and the decision of partial RTW may be associated with findings of a worsened prognosis, such as existence of metastasis [47].

Furthermore, we used Fine-Gray regression analysis in order to investigate predictors of the time to full RTW, but only studying full RTW underestimates the proportion of individuals who return to the labor market. These results show that this is especially so for cancer sites with a high partial/full RTW ratio (e.g., gastric and esophageal cancers).

Strengths and limitations

One of the strengths of the present study was the enrollment of a large group of subjects; approximately 1300 Japanese employees who experienced a period of sickness absence due to cancer were included in the study, the first large-scale Japanese RTW study of cancer survivors. Additionally, the follow-up rate was very high (almost 100 %) because the sickness-absence register was company-enforced, with OPs consistently recording all cancer cases arising in the workforce and certifying sickness absences. With this system, there was less subject selection and loss to follow-up biases that may have possibly affected other studies. Furthermore, we used an objective measurement of sickness absence; the present study was based on data from clinically certified sickness absence using physicians’ certificates. Utilization of clinically made ICD-10 diagnoses of the subjects’ cancers allowed for a higher validity and reliability than categorization by other diseases, such as psychiatric diseases. Another strength of our study was that we used the partial RTW system, investigating “the partial/full RTW ratio judged by OPs at RTW” and “the cumulative partial/full RTW rate.”

When interpreting the results of the present study, several limitations should be noted. First, the medical information of the subjects was not available for use in the present study, such as stage of cancer, pathological degree of malignancy, and type of treatment (surgery, chemotherapy, radiation therapy). Second, we could not deny the existence of comorbidities in the subjects, due to the registration of only one diagnosis per episode of sickness absence by the OPs. Subjects may have had other disorders during the sickness absence, such as depression or ileus after iliac surgery, or other symptoms such as depressive mood, anxiety, or sleep disorders, often found in cancer survivors. Knowledge of comorbidities is necessary due to their influence on time to RTW [24]. Third, no differentiation was made between subjects who may have had
previous episodes of cancer prior to working at the company in question, or subjects who experienced recurrence or other types of cancer after the study period. Fourth, because the majority of the subjects were male, caution is necessitated for generalizations across the entire workforce based on the present results. Fifth, it is very important to note that the initial date of sickness absence may have been significantly different from the date of diagnosis, or the date of the start of the illness. Sixth, it might be suspicious to have the proportional hazard assumption according to the visual inspection of the output. However, the logistic regression model showed, the same as the Fine-Gray proportional hazard regression model, that “57 years or older (reference: 48 years or younger),” “esophageal cancer (reference: gastric cancer),” “lung cancer,” “hepatic, pancreatic cancer,” and “blood malignancies” had lower probabilities of full RTW. Seventh, different forms of cohort biases might be introduced. This is because all individuals are pooled in the analyses, regardless of their year of sickness absence. Since there have obviously been changes in cancer treatments, RTW policies, and other factors over the years, this could (if there are systematic differences) be a problem.

Future studies

Further clarification of the predictors of sickness absence due to cancer is required to better support the drafting of a RTW strategy for cancer survivors. The following predictors of time to RTW require further investigation: disorder-related factors (diagnosis, stage of cancer, content of medical treatment) and environmental factors (job demand, supervisory support, and co-worker support). Recurrent sickness absence after RTW among cancer survivors should also be investigated for tertiary prevention, in particular, recurrent sickness absence due to psychiatric disorders (such as depression, anxiety disorders) after RTW. Research on mental health problems may be important for the improvement of quality of life for cancer survivors.

Conclusion

More than half of the total cancer survivors returned to work within the 365-day period following their initial day of sickness absence. The cumulative RTW rate was dependent on the type of cancer. Older employees may require a longer time to full RTW. Occupational health professionals may better support cancer survivors for RTW, with the knowledge that cumulative RTW rates vary by cancer type. For cancer survivors, it is very important for companies (especially small- and medium-sized ones) to establish and improve their RTW support systems (e.g., partial RTW system), with the knowledge that the median time to RTW is expected to be at least a few months.

Acknowledgments We are very grateful to Dr. Kousuke Kiyohara (Department of public health, Tokyo Womens’ Medical University) and Dr. Atsushi Goto (Department of Public Health, Tokyo Womens’ Medical University) for the statistical analysis of this study.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Mehnert A. Employment and work-related issues in cancer survivors. Crit Rev Oncol/Hematol. 2011;77(2):109–30.
2. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROcare-4 data. Lancet Oncol. 2007;8(9):784–96.
3. Ministry of Health L, Welfare, Japan.: Labor Contract Act. Ministry of Health, Labor, Welfare, Japan 2007.
4. Feuerstein M, Todd BL, Moskwitz MC, Bruns GL, Stoler MR, Nassif T, et al. Work in cancer survivors: a model for practice and research. J Cancer Surviv : Res Pract. 2010;4(4):415–37.
5. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A et al.: Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2014.
6. Verbeek J, Spelten E, Kammeijer M, Sprangers M. Return to work of cancer survivors: a prospective cohort study into the quality of rehabilitation by occupational physicians. Occup Environ Med. 2003;60(5):352–7.
7. Francisci S, Capocaccia R, Grande E, Sant Aquilani M, Simonetti A, Allemani C, et al. The cure of cancer: a European perspective. Eur J Cancer. 2009;45(6):1067–79.
8. Aziz NM. Cancer survivorship research: state of knowledge, challenges and opportunities. Acta Oncol. 2007;46(4):417–32.
9. Marino P, Luis Sagaon T, Laetitia M, le Anne-Gaelle CS. Sex differences in the return-to-work process of cancer survivors 2 years after diagnosis: results from a large French population-based sample. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(10):1277–84.
10. Ito Y, Miyashiro I, Ito H, Hosono S, Chihara D, Nakata-Yamada K, et al. Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci. 2014;105(11):1480–6.
11. Takahashi M, Kai I, Muto T. Discrepancies between public perceptions and epidemiological facts regarding cancer prognosis and incidence in Japan: an Internet survey. Jpn J Clin Oncol. 2012;42(10):919–26.
12. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H. Japan Cancer Surveillance Research G: Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer
Incidence in Japan (MCII) project. Jpn J Clin Oncol. 2014;44(4):388–96.
13. Tamminga SJ, de Boer AG, Verbeek JH, Frings-Dresen MH. Return-to-work interventions integrated into cancer care: a systematic review. Occup Environ Med. 2010;67(9):639–48.
14. Ministry of Health L, Welfare, Japan.: “Gankanja keikensya no syourousien no arikata ni kansuru kensetsu houkokusyo” (in Japanese). 2014.
15. Amir Z, Moran T, Walsh L, Iddenden R, Luker K. Return to paid work after cancer: a British experience. J Cancer Surviv: Res Pract. 2007;1(2):129–36.
16. Roelen CA, Koopmans PC, Anema JR, van der Beek AJ. Recurrence of medically certified sickness absence according to diagnosis: a sickness absence register study. J Occup Rehabil. 2010;20(1):113–21.
17. Roelen CA, Koopmans PC, Groothoff JW, van der Klink JJJ, Bulthman U. Sickness absence and full return to work after cancer: 2-year follow-up of register data for different cancer sites. Psycho-Oncology. 2011;20(9):1001–6.
18. Gordon LG, Beesley VL, Lynch BM, Mihala G, McGrath C, Graves N, et al. The return to work experiences of middle-aged Australian workers diagnosed with colorectal cancer: a matched cohort study. BMC Public Health. 2014;14:963.
19. Spelten ER, Verbeek JH, Uitterhoeve AL, Ansink AC, van der Lelie J, de Reijke TM, et al. Cancer, fatigue and the return of patients to work-a prospective cohort study. Eur J Cancer. 2003;39(11):1562–7.
20. Saito N, Takahashi M, Sairenchi T, Muto T. The impact of breast cancer on employment among Japanese women. J Occup Health. 2014;56(1):49–55.
21. Torp S, Nielsen RA, Gudbergsson SB, Dahl AA. Worksite adjustments and work ability among employed cancer survivors. Support Care Cancer. 2012;20(9):2149–56.
22. Spelten ER, Sprangers MA, Verbeek JH. Factors reported to influence the return to work of cancer survivors: a literature review. Psycho-Oncology. 2002;11(2):124–31.
23. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
24. Cooper AF, Hankins M, Rixon L, Eaton E, Grunfeld EA. Distinct work-related, clinical and psychological factors predict return to work following treatment in four different cancer types. Psycho-Oncology. 2013;22(3):659–67.
25. Sjovall K, Attner B, Englund M, Lithman T, Noreen D, Gunnars B, et al. Sickness absence among cancer patients in the pre-diagnostic and the post-diagnostic phases of five common forms of cancer. Support Care Cancer. 2012;20(4):741–7.
26. Short PF, Vasey JJ, Tuneceli K. Employment pathways in a large cohort of adult cancer survivors. Cancer. 2005;103(6):1292–301.
27. Carlsen K, Harling H, Pedersen J, Christensen KB, Osler M: The transition between work, sickness absence and pension in a cohort of Danish colorectal cancer survivors. BMJ open 2013, 3(2).
28. Murray K, Lam KB, McLoughlin DC, Sadhra SS. Predictors of return to work in cancer survivors in the royal air force. J Occup Rehabil. 2015;25(1):153–9.
29. Hensing G. Swedish Council on Technology Assessment in Health Care (SBU). chapter 4. methodological aspects in sickness-absence research. Scandinavian J Public Health Suppl. 2004;63:44–8.
30. Bottcher HM, Steimann M, Rotsch M, Zurborn KH, Koch U, Bergelt C. Occupational stress and its association with early retirement and subjective need for occupational rehabilitation in cancer patients. Psycho-Oncology. 2013;22(8):1807–14.
31. Roelen CA, Koopmans PC, Schellart AJ, van der Beek AJ. Resuming work after cancer: a prospective study of occupational register data. J Occup Rehabil. 2011;21(3):431–40.
32. Sampere M, Gimeno D, Serra C, Plana M, Martinez JM, Delelos GL, et al. Organizational return to work support and sick leave duration: a cohort of Spanish workers with a long-term non-work-related sick leave episode. J Occupation Environ Med / Am College Occupation Environ Med. 2011;53(6):674–9.
33. Horsboel TA, Nielsen CV, Andersen NT, Nielsen B, de Thurah A. Risk of disability pension for patients diagnosed with haematological malignancies: a register-based cohort study. Acta Oncol. 2014;53(6):724–34.
34. The clinical guideline of haematological malignancies 2013 (in Japanese).
35. Harrison’s principal of internal medicine 15th edition volume 1.
36. Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE, et al. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer. 2006;106(4):751–8.
37. Henselmann I, Helgeson VS, Seltman H, de Vries J, Sanderman R, Ranchor AV. Identification and prediction of distress trajectories in the first year after a breast cancer diagnosis. Health Psychol: Off J Div Health Psychol, Am Psychol Assoc. 2010;29(2):160–8.
38. Nissim R, Gagliese L, Rodin G. The desire for hastened death in individuals with advanced cancer: a longitudinal qualitative study. Soc Sci Med. 2009;69(2):165–71.
39. van Muijen P, Duijts SF, van der Beek AJ, Anema JR. Prognostic factors of work disability in sick-listed cancer survivors. J Cancer Survivor: Res Pract. 2013;7(4):582–91.
40. Meinert A, Koch U. Predictors of employment among cancer survivors after medical rehabilitation–a prospective study. Scandinavian J Work, Environ Health. 2013;39(1):76–87.
41. van Muijen P, Weevers NL, Snels IA, Duijts SF, Bruinvels DJ, Schellart AJ, et al. Predictors of return to work and employment in cancer survivors: a systematic review. Europ J Cancer Care. 2013;22(2):144–60.
42. Taskila T, Lindbohm ML. Factors affecting cancer survivors’ employment and work ability. Acta Oncol. 2007;46(4):446–51.
43. Ministry of Health L, Welfare, Japan.: The patient survey 2008 (in Japanese). 2008.
44. Christensen KB, Andersen PK, Smith-Hansen L, Nielsen ML, Kristensen TS. Analyzing sickness absence with statistical models for survival data. Scandinavian J Work, Environ Health. 2007;33(3):233–9.
45. Nilsson M, Olsson M, Wennmalm-Larsen A, Petersson LM, Alexanderson K. Return to work after breast cancer: women’s experiences of encounters with different stakeholders. Europ J Oncol Nurs: Off J Europ Oncol Nursing Soc. 2011;15(3):267–74.
46. Satariano WA, De Lorenzo GN. The likelihood of returning to work after breast cancer. Public Health Rep. 1996;111(3):236–41.
47. Ohguri T, Narai R, Funahashi A, Nishiura C, Yamashita T, Yarita K, et al. Limitations on work and attendance rates after employees with cancer returned to work at a single manufacturing company in Japan. J Occup Health. 2009;51(3):267–72.